HC Wainwright Has Bearish Forecast for Neurogene Q3 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Neurogene in a research report issued on Tuesday, August 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($1.14) per share for the quarter, down from their prior estimate of ($1.08). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.45) EPS, Q1 2026 earnings at ($1.21) EPS, Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at ($1.26) EPS, Q4 2026 earnings at ($1.28) EPS and FY2026 earnings at ($4.98) EPS.

A number of other equities research analysts also recently commented on NGNE. Baird R W lowered Neurogene from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 16th. BMO Capital Markets reissued an “outperform” rating and issued a $26.00 price objective (up from $22.00) on shares of Neurogene in a research note on Thursday, June 12th. Robert W. Baird downgraded shares of Neurogene from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $38.00 to $24.00 in a report on Friday, May 16th. Finally, Craig Hallum started coverage on Neurogene in a research report on Tuesday, June 17th. They set a “buy” rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Neurogene has a consensus rating of “Moderate Buy” and a consensus price target of $46.17.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $20.51 on Thursday. The company has a market cap of $292.68 million, a P/E ratio of -4.76 and a beta of 1.69. The firm’s fifty day moving average is $20.34 and its two-hundred day moving average is $17.28. Neurogene has a 52-week low of $6.88 and a 52-week high of $74.49.

Neurogene (NASDAQ:NGNE) last released its earnings results on Monday, August 11th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.10.

Hedge Funds Weigh In On Neurogene

A number of large investors have recently made changes to their positions in NGNE. Geode Capital Management LLC grew its holdings in Neurogene by 6.4% during the 4th quarter. Geode Capital Management LLC now owns 234,625 shares of the company’s stock valued at $5,365,000 after purchasing an additional 14,026 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Neurogene by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock valued at $124,000 after buying an additional 1,397 shares during the period. Barclays PLC grew its stake in shares of Neurogene by 18.0% during the fourth quarter. Barclays PLC now owns 17,533 shares of the company’s stock valued at $401,000 after buying an additional 2,674 shares during the last quarter. Mariner LLC bought a new position in shares of Neurogene during the fourth quarter valued at approximately $239,000. Finally, XTX Topco Ltd purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $349,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.